Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) EBIT Margin (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed EBIT Margin for 6 consecutive years, with 69.76% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin fell 121.0% to 69.76% in Q3 2025 year-over-year; TTM through Sep 2025 was 94.23%, a 747.0% decrease, with the full-year FY2024 number at 74.32%, up 5100.0% from a year prior.
  • EBIT Margin was 69.76% for Q3 2025 at Vivos Therapeutics, up from 127.28% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 198.2% in Q4 2021 to a low of 182.19% in Q1 2022.
  • A 5-year average of 98.75% and a median of 121.05% in 2021 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: soared 38714bps in 2021, then tumbled -35169bps in 2022.
  • Vivos Therapeutics' EBIT Margin stood at 198.2% in 2021, then tumbled by -177bps to 153.49% in 2022, then grew by 14bps to 131.9% in 2023, then skyrocketed by 42bps to 75.88% in 2024, then rose by 8bps to 69.76% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's EBIT Margin are 69.76% (Q3 2025), 127.28% (Q2 2025), and 129.91% (Q1 2025).